Investors

Sepsis is implicated in 20% of all deaths. MicrosensDx is developing its novel sepsis IP into the ox-PTX sepsis test - to confront a profound unmet medical need, to improve sepsis diagnosis and prognosis testing. Its prospective routine early warning testing and treatment monitoring test for inflammation and sepsis risk profiling could save lives and money.

MicrosensDx has collaborated with Imperial College, UK and more recently with ProteoGenix, France, to develop an ELISA based test for ox-PTX3.

By focussing research efforts on this problematic and potentially lucrative area of sepsis diagnosis and treatment, MicrosensDx’s objectives are to achieve technical and clinical milestones for its transformational biomarker test for sepsis (ox-PTX3 sepsis test).

We have announced collaborations to develop a more effective and specific test for the devastating disease - Read more here

Infectious disease sample management is a critical ‘front-end’ to infectious disease testing. Sampling errors account for up to 70% of lab errors. In addition, MicrosensDx provides unique sample management solutions, services and products (RapiPREP).

To learn more about MicrosensDx and to discuss investment opportunities, please contact us.